ISRCTN82062639已完成4 期
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A randomised double-blind placebo-controlled trial (SEESAW)
niversity of Leicester0 个研究点目标入组 68 人开始时间: 2016年7月20日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35441435/ (added 26/10/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and postmenopausal female participants aged between 30-70 years of age inclusive
- •2. Type 2 diabetes on diet and lifestyle control or stable dose of metformin only for at least 3 months
- •3. Stable weight (less than 5% change in body weight in last 3 months) – determined by self-reporting or documentation in clinical records
- •4. HbA1c 48-86mmol/mol (6.5 - 10%)
- •5. eGFR=60ml/min/1.73m2
- •6. BMI = 25kg/m2
- •7. Able and willing to give informed consent
- •8. Able to understand English
排除标准
- •1. Females who are not postmenopausal (as menstrual cycle can affect appetite hormone concentrations) which is defined as 2 years post last menstrual period <50 years of age or 1 year post last menstrual period >50 years of age.”
- •2. Type 2 diabetes on any other glucose lowering treatment except metformin
- •3. Patients with Type 1 diabetes
- •4. Patients on loop diuretics
- •5. Age <30 years and >70 years
- •6. BMI <25kg/m2
- •7. Not able to give informed consent
- •8. Not able to understand English
- •9. Moderate to severe renal impairment (eGFR<60ml/min/1.73m2)
- •10. Unstable diabetes i.e. HbA1c >86mmol/mol (10%), recent hospital admission with diabetic emergency in last 3 months
- •11. Patients with familial renal glycosuria
- •12. Patients with recurrent balanitis, vaginal or urinary tract infections
- •13. Shift workers
- •14. Patients who have participated in another study of an investigational medicinal product in the last 3 months
- •15. Active malignancy
- •16. Serious illness with a life-expectancy of less than 1 year
- •17. Hypersensitivity to Empagliflozin (Jardiance™) or to any of the excipients
- •18. Patients with latent autoimmune diabetes in adults (LADA)
- •19. Patients with a history of chronic pancreatitis
- •20. Evidence of conditions that lead to restricted food intake or severe dehydration
- •21. Patients with a history of excessive alcohol consumption
- •22. Patients on a severely calorie restricted diet (i.e., =800 calories per day)
研究者
相似试验
进行中(未招募)
1 期
SEESAW (SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation)Type 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-001594-40-GBniversity of Leicester76
已完成
4 期
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.Diabetes Mellitus, Type 2NCT02798744University of Leicester68
招募中
2 期
SGLT2 Inhibition with Empagliflozin on Metabolic, Cardiac and Renal Outcomes in Recent Cardiac Transplant RecipientsCardiac transplantRenal diseaseCardiovascular - Other cardiovascular diseasesMetabolic and Endocrine - DiabetesRenal and Urogenital - Kidney diseaseDiabetesACTRN12622000978763Garvan Institute of Medical Research100
尚未招募
Unknown
Effects of SGLT2 inhibitors on appetite in patients with type 2 diabetesJPRN-jRCT1050220190in Kazuko58
已完成
2 期
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE StudyInappropriate ADH SyndromeNCT02729766University Hospital, Basel, Switzerland15
